Schizophrenia and Nicotine Dependence

What Psychopharmacological Treatment Options are Available for the Duo Perturbationes?

Research output: Contribution to journalArticle

Abstract

Nicotine dependence has progressively become a foremost community health interest in both the developed and developing nations due to the economic burden and health-related problems. Smoking was significantly higher among patients with schizophrenia in comparison to the general population. Nicotine dependence is not only associated with public stress, but among patients with schizophrenia, smoking brings major challenges to the management. Nicotine may diminish the therapeutic efficacy of the bioavailability of the psychopharmacological agents in-vivo. These duo perturbations, i.e. two clinical conditions co-existed may prevent psychotic symptoms remission among patients suffering from schizophrenia who smoke at the same time. The aim of this review was to highlight the role of pharmacological treatment options and strategies for patients with nicotine dependence in schizophrenia with emphasis on the underlying neurobiological process. The role of nicotine replacement therapy, i.e. norepinephrine-dopamine reuptake inhibition (NDRI) e.g. bupropion and selective partial agonist of α4β2 and full α7-nicotinic acetylcholine receptor e.g. varenicline was deliberated. An ideal choice of drug targets for patients with schizophrenia with nicotine dependence is pivotal to foster a better therapeutic alliance.

Original languageEnglish
Pages (from-to)173-181
Number of pages9
JournalCurrent Drug Targets
Volume20
Issue number2
DOIs
Publication statusPublished - 1 Jan 2019

Fingerprint

Tobacco Use Disorder
Nicotine
Schizophrenia
Smoking
Therapeutics
Bupropion
Health
Nicotinic Receptors
Developed Countries
Smoke
Biological Availability
Developing Countries
Dopamine
Norepinephrine
Economics
Pharmacology
Pharmaceutical Preparations
Population

Keywords

  • drug targets
  • Nicotine dependence
  • psychoactive agents
  • schizophrenia
  • smoking
  • treatment options.

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

@article{8cb2cddafe364624ab1728296c9e3258,
title = "Schizophrenia and Nicotine Dependence: What Psychopharmacological Treatment Options are Available for the Duo Perturbationes?",
abstract = "Nicotine dependence has progressively become a foremost community health interest in both the developed and developing nations due to the economic burden and health-related problems. Smoking was significantly higher among patients with schizophrenia in comparison to the general population. Nicotine dependence is not only associated with public stress, but among patients with schizophrenia, smoking brings major challenges to the management. Nicotine may diminish the therapeutic efficacy of the bioavailability of the psychopharmacological agents in-vivo. These duo perturbations, i.e. two clinical conditions co-existed may prevent psychotic symptoms remission among patients suffering from schizophrenia who smoke at the same time. The aim of this review was to highlight the role of pharmacological treatment options and strategies for patients with nicotine dependence in schizophrenia with emphasis on the underlying neurobiological process. The role of nicotine replacement therapy, i.e. norepinephrine-dopamine reuptake inhibition (NDRI) e.g. bupropion and selective partial agonist of α4β2 and full α7-nicotinic acetylcholine receptor e.g. varenicline was deliberated. An ideal choice of drug targets for patients with schizophrenia with nicotine dependence is pivotal to foster a better therapeutic alliance.",
keywords = "drug targets, Nicotine dependence, psychoactive agents, schizophrenia, smoking, treatment options.",
author = "Theng, {Yoong Mei} and Suzaily Wahab and {Abdul Wahab}, {Noor Alaudin} and Hatta Sidi and Srijit Das",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1389450118666171017163741",
language = "English",
volume = "20",
pages = "173--181",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Schizophrenia and Nicotine Dependence

T2 - What Psychopharmacological Treatment Options are Available for the Duo Perturbationes?

AU - Theng, Yoong Mei

AU - Wahab, Suzaily

AU - Abdul Wahab, Noor Alaudin

AU - Sidi, Hatta

AU - Das, Srijit

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Nicotine dependence has progressively become a foremost community health interest in both the developed and developing nations due to the economic burden and health-related problems. Smoking was significantly higher among patients with schizophrenia in comparison to the general population. Nicotine dependence is not only associated with public stress, but among patients with schizophrenia, smoking brings major challenges to the management. Nicotine may diminish the therapeutic efficacy of the bioavailability of the psychopharmacological agents in-vivo. These duo perturbations, i.e. two clinical conditions co-existed may prevent psychotic symptoms remission among patients suffering from schizophrenia who smoke at the same time. The aim of this review was to highlight the role of pharmacological treatment options and strategies for patients with nicotine dependence in schizophrenia with emphasis on the underlying neurobiological process. The role of nicotine replacement therapy, i.e. norepinephrine-dopamine reuptake inhibition (NDRI) e.g. bupropion and selective partial agonist of α4β2 and full α7-nicotinic acetylcholine receptor e.g. varenicline was deliberated. An ideal choice of drug targets for patients with schizophrenia with nicotine dependence is pivotal to foster a better therapeutic alliance.

AB - Nicotine dependence has progressively become a foremost community health interest in both the developed and developing nations due to the economic burden and health-related problems. Smoking was significantly higher among patients with schizophrenia in comparison to the general population. Nicotine dependence is not only associated with public stress, but among patients with schizophrenia, smoking brings major challenges to the management. Nicotine may diminish the therapeutic efficacy of the bioavailability of the psychopharmacological agents in-vivo. These duo perturbations, i.e. two clinical conditions co-existed may prevent psychotic symptoms remission among patients suffering from schizophrenia who smoke at the same time. The aim of this review was to highlight the role of pharmacological treatment options and strategies for patients with nicotine dependence in schizophrenia with emphasis on the underlying neurobiological process. The role of nicotine replacement therapy, i.e. norepinephrine-dopamine reuptake inhibition (NDRI) e.g. bupropion and selective partial agonist of α4β2 and full α7-nicotinic acetylcholine receptor e.g. varenicline was deliberated. An ideal choice of drug targets for patients with schizophrenia with nicotine dependence is pivotal to foster a better therapeutic alliance.

KW - drug targets

KW - Nicotine dependence

KW - psychoactive agents

KW - schizophrenia

KW - smoking

KW - treatment options.

UR - http://www.scopus.com/inward/record.url?scp=85060018010&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060018010&partnerID=8YFLogxK

U2 - 10.2174/1389450118666171017163741

DO - 10.2174/1389450118666171017163741

M3 - Article

VL - 20

SP - 173

EP - 181

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 2

ER -